Control strategies for difficult sedation;Estrategias de control de la sedación difícil

Medicina Intensiva

Volumn 32, Issue SUPPL. 1, 2008, Pages 31-37

  Chamorro Jambrina, C ^a   Romera, M A ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Clonidine; Critically ill patient; Haloperidol; Mechanical ventilation; Midazolam; Propofol; Remifentanil; Sedation; Tolerance; Withdrawal

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; DEXMEDETOMIDINE; FENTANYL; HALOPERIDOL; MIDAZOLAM; MORPHINE; PROPOFOL; REMIFENTANIL;

ARTIFICIAL VENTILATION; CONTINUOUS INFUSION; CONTROL STRATEGY; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG INDUCED DISEASE; ELECTROCARDIOGRAPHY; GASTROINTESTINAL TOXICITY; HEMODYNAMICS; HUMAN; INTENSIVE CARE UNIT; PHYSICIAN; POSTOPERATIVE PAIN; PROPOFOL INFUSION SYNDROME; REVIEW; SEDATION;

ANESTHETICS, INTRAVENOUS; CRITICAL ILLNESS; DEEP SEDATION; HUMANS; RESPIRATION, ARTIFICIAL; TIME FACTORS;

EID: 45749122405     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Ramsay MA. Intensive care: problems of over-and under sedation. Best Practice Anaesthesiol. 2000;14:419-32.
2. Woods JC, Mion LC, Connor JT, Viray F, Jahan L, Huber C, et al. Severe agitation among ventilated medical intensive care unit patients: frequency, characteristics and outcomes. Intensive Care Med. 2004;30:1066-72.
3. Shapiro BA. Sedation for mechanically ventilated patients: back to basics please! Crit Care Med. 1994;22:904-6.
4. Chamorro C, Romera MA, Silva JA. Importancia de la sedoanalgesia en los pacientes en ventilación mecánica. Med Intensiva. 2003;1 Suppl:2-4.
5. Riker RR, Fraser GL. Adverse events associated with sedatives, analgesics, and other drugs that provide patient comfort in the intensive care unit. Pharmacotherapy. 2005;25:S8-18.
6. De Gaudio AR, Rinaldi S. Sedation in PACU: indications, monitoring, complications. Curr Drug Targets. 2005;6:729-40.
7. Carrasco G. Instruments for monitoring intensive care unit sedation. Crit Care Med. 2000;4:217-25.
8. Chamorro C, Martínez-Melgar JL, Barrientos R, Grupo de Trabajo de Analgesia y Sedación de la SEMICYUC. Monitorización de la sedación. Med Intensiva. 2008;32:45-52.
9. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med. 2002;7:201-4.
10. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352:2211-21.
11. Volles DF, McGory R. Pharmacokinetic considerations. Crit Care Clin. 1999;15:55-75.
12. Fujita M, Woods SW, Verhoeff NP, Abi-Dargham A, Baldwin RM, Zoghbi SS, et al. Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans. Eur J Pharmacol. 1999;368:161-72.
13. Vree TB, Shimoda M, Driessen JJ, Guelen PJ, Janssen TJ, Termond EF, et al. Decreased plasma albumin concentration results in increased volume of distribution and decreased elimination of midazolam in intensive care patients. Clin Pharmacol Ther. 1989;46:537-44.
14. Bertucci C, Domenici E. Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance. Curr Med Chem. 2002;9:1463-81.
15. Malacrida R, Fritz ME, Suter PM, Crevoisier C. Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients. Crit Care Med. 1992;20:1123-6.
16. Shafer A, Doze VA, White PF. Pharmacokinetic variability of midazolam infusions in critically ill patients. Crit Care Med. 1990;18:1039-41.
17. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42:819-50.
18. Yeates RA, Laufen H, Zimmermann T, Schumacher T. Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin, clarithromycin, and the azalide azithromycin. Int J Clin Pharmacol Ther. 1997;35:577-9.
19. Behne M, Asskali F, Steuer A, Forster H. Continuous midazolam infusion for sedation of respirator patients. Anaesthesist. 1987;36:228-32.
20. Hadbavny AM, Hoyt JW. Sedatives and analgesics in Critical Care. En: Shoemaker W, Ayres S, Grenvik A, Holbrook P, editors. Textbook of Critical Care. 4th edition. Philadelphia: WB Saunders; 2000. p. 961-71.
21. Nejman AM. Sedatives and analgesics. En: Civetta JM, Taylor RW, Kirby RR, editors. Critical Care. 3rd edition. Philadelphia: Lippincott-Raven; 1997. p. 821-36.
22. Strobel W, Ritz R. Sedatives in critical care. En: Webb MJ, Shapiro MJ, Singer M, Suter PM, editors. Textbook of Critical Care. Oxford: Oxford Medical Publications; 1999. p. 1274-7.
23. Cammarano WB, Drasner K, Katz JA. Pain control, sedation, and use of muscle relaxants. En: Hall JB, Schmidt GA, Wood LH, editors. Principles of Critical Care. 2nd edition. New York: McGraw-Hill; 1998. p. 87-109.
24. Mazzeo AJ. Sedation for the mechanically ventilated patient. Crit Care Clin. 1995;11:937-55.
25. Lund N, Papadakos PJ. Barbiturates, neuroleptics, and propofol for sedation. Crit Care Clin. 1995;11:875-86.
26. Blanco J, Martínez JM, Collado J. Sedación con benzodiacepinas en el paciente grave. En: Castañeda FJ, editor. Sedación y analgesia en el paciente grave. Medicina clínica práctica. Barcelona: Edika Med; 1994. p. 39-56.
27. Sánchez Izquierdo Riera JA, Caballero Cubedo RE, Pérez Vela JL, Ambros Checa A, Cantalapiedra Santiago JA, Alted López E. Propofol versus midazolam: safety and efficacy for sedating the severe trauma patient. Anesth Analg. 1998;86:1219-24.
28. Sandiumenge Camps A, Sánchez-Izquierdo Riera JA, Toral Vázquez D, Sa Borges M, Peinado Rodríguez J, Alted López E. Midazolam and 2% propofol in long-term sedation of traumatized, critically ill patients: Efficacy and safety comparison. Crit Care Med. 2000;28:3612-9.
29. Barrientos Vega R, Sánchez Soria M, Morales García C, Robas Gómez A, Cuenca-Boy R, Ayensa Rincón A. Prolonged sedation of critically ill patients with midazolam or propofol: impact on weaning and costs. Crit Care Med. 1997;25:33-40.
30. Swart EL, van Schijndel RJ, van Loenen AC, Thijs LG. Continuous infusion of lorazepam versus midazolam in patients in the intensive care unit: sedation with lorazepam is easier to manage and is more cost-effective. Crit Care Med. 1999;27:1461-5.
31. Swart EL, Zuideveld KP, de Jongh J, Danhof M, Thijs LG, Strack van Schijndel RM. Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. Br J Clin Pharmacol. 2004;57:135-45.
32. Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002;30:119-41.
33. Mattia C, Savoia G, Paoletti F, Piazza O, Albanese D, Amantea B, et al. SIAARTI recommendations for analgo-sedation in intensive care unit. Minerva Anestesiol. 2006;72:769-805.
34. Martin J, Franck M, Fischer M, Spies C. Sedation and analgesia in German intensive care units: how is it done in reality? Results of a patient-based survey of analgesia and sedation. Intensive Care Med. 2006;32:1137-42.
35. Aitkenhead AR, Pepperman ML, Willatts SM, Coates PD, Park GR, Bodenham AR, et al. Comparison of propofol and midazolam for sedation in critically ill patients. Lancet. 1989;II:704-9.
36. Beyer R, Seyde WC. Propofol versus midazolam. Long term sedation in the intensive care unit. Anaesthesist. 1992;41:335-41.
37. Carrasco G, Molina R, Costa J, Soler JM, Cabre L. Propofol vs midazolam in short-, medium-, and long-term sedation of critically ill patients. A cost-benefit analysis. Chest. 1993;103:557-64.
38. Kress JP, O'Connor MF, Pohlman AS, Olson D, Lavoie A, Toledano A, et al. Sedation of critically ill patients during mechanical ventilation: a comparison of propofol and midazolam. Am J Respir Crit Care Med. 1996;153:1012-8.
39. Chamorro C, de Latorre FJ, Montero A, Sánchez Izquierdo JA, Jareno A, Moreno JA, et al. Comparative study of propofol versus midazolam in the sedation of critically ill patients: results of a prospective, randomized, multicenter trial. Crit Care Med. 1996;24:932-9.
40. Weinbroum AA, Halpern P, Rudick V, Sorkine P, Freedman M, Geller E. Midazolam versus propofol for long-term sedation in the ICU: a randomized prospective comparison. Intensive Care Med. 1997;23:1258-63.
41. Helmy SAK, Al-Attiyah RJ. The immunomodulatory effects of prolonged intravenous infusion of propofol versus midazolam in critically ill surgical patients. Anaesthesia. 2001;56:4-8.
42. Payen JF, Chanques G, Mantz J, Hercule C, Auriant I, Leguillou JL, et al. Current practices in sedation and analgesia for mechanically ventilated critically ill patients: A prospective multicenter patient-based study. Anesthesiology. 2007;106:687-95.
43. Chamorro C, Romera MA, Márquez J, Pardo C, Valdivia M. Therapeutic failure with propofol in the sedation of critical patients. A definition proposal. Intensive Care Med. 2004;30 Suppl 1:S203.
44. Barrientos-Vega R, Sánchez-Soria MM, Morales-García C, Cuenca-Boy R, Castellano-Hernández M. Pharmacoeconomic assessment of propofol 2% used for prolonged sedation. Crit Care Med. 2001;29:317-22.
45. Albrecht S, Ihmsen H, Suchodolski K, Frenkel C, Schuttler J. Analgo-sedation in intensive care: a quantitative, EEG-based trial with propofol 1% and 2%. Anaesthesist. 1999;48:794-801.
46. Vasile B, Rasulo F, Candiani A, Latronico N. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 2003;29:1417-25.
47. Bray RJ. The propofol infusion syndrome in infants and children: can we predict the risk? Curr Opin Anaesthesiol. 2002; 15:339-42.
48. Parke TJ, Stevens JE, Rice ASC, Greenaway CL, Bray RJ, Smith PJ, et al. Metabolic acidosis and fatal myocardial failure after propofol infusions in children: five case reports. BMJ. 1992; 305:613-6.
49. Cremer OL, Moons KGM, Bouman EAC, Kruijswijk JE, de Smet AMGA, Kalkman CJ. Long-term propofol infusion and cardiac failure in adult head-injured. Lancet. 2001;357:117-8.
50. Perrier ND, Baerga-Varela Y, Murray MJ. Death related to propofol use in an adult patient. Crit Care Med. 2000;28:3071-4.
51. Ahlen K, Buckley CJ, Goodale DB, Pulsford AH. The 'propofol infusion syndrome': the facts, their interpretation and implications for patient care. Eur J Anaesthesiol. 2006;23:990-8.
52. Fudickar A, Bein B, Tonner PH. Propofol infusion syndrome in anaesthesia and intensive care medicine. Curr Opin Anaesthesiol. 2006;19:404-10.
53. Devlin JW, Lau AK, Tanios MA. Propofol associated hypertriglyceridemia and pancreatitis in the intensive care unit: an analysis of frequency and risk factors. Pharmacotherapy. 2005;25:1348-52.
54. Buckley PM. Propofol in patients needing long term sedation in intensive care: an assessment of the development of tolerance. A pilot study. Intensive Care Med. 1997;23:969-74.
55. Chamorro C, Romera MA, Márquez J, Pardo C, Valdivia M. Therapeutic failure with midazolam in the sedation of critical patients. A definition proposal. Intensive Care Med. 2004;30 Suppl 1:S177.
56. Pohlman AS, Simpson KP, Hall JB. Continuous intravenous infusions of lorazepam versus midazolam for sedation during mechanical ventilatory support: a prospective, randomized study. Crit Care Med. 1994;22:1241-7.
57. Cammarano WB, Pittet JF, Weitz S, Schlobohm RM, Marks JD. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Crit Care Med. 1998;26:676-84.
58. Laviñeta E, Alberdi F, Arcega I, Luque O, Romo E, García J. Síndrome de deprivación tras sedación prolongada en UCI. Med Intensiva. 1997;21:269-73.
59. Pandharipande P, Shintani A, Peterson J, Pun BT, Wilkinson GR, Dittus RS, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology. 2006;104:21-6.
60. Chamorro C, Romera MA, Pardo C. Analgesia y sedación del paciente crítico. Presente y futuro. Med Intensiva. 2004;2 Suppl 3:1-4.
61. Shelly MP, Sultan MA, Bodenham A, Park GR. Midazolam infusions in critically ill patients. Eur J Anaesthesiol. 1991;8:21-7.
62. Ritz R. Benzodiacepine sedation in adult ICU patients. Intensive Care Med. 1991;17 Suppl 1:S11-4.
63. Brown C, Albrecht R, Pettit H, McFadden T, Schermer C. Opioid and benzodiazepine withdrawal syndrome in adult burn patients. Am Surg. 2000;66:367-71.
64. Korak-Leiter M, Likar R, Oher M, Trampitsch E, Ziervogel G, Levy JV, et al. Withdrawal following sufentanil/propofol and sufentanil/midazolam sedation in surgical ICU patients: correlation with central nervous parameters and endogenous opioids. Intensive Care Med. 2005;31:380-7.
65. Ely EW, Inouye SK, Bernard GR, Gordon S, Francis J, May L, et al. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA. 2001;286:2703-10.
66. Freire AX, Afessa B, Cawley P, Phelps S, Bridges L. Characteristics associated with analgesia ordering in the intensive care unit and relationships with outcome. Crit Care Med. 2002;30:2468-72.
67. Pardo C, Munoz T, Chamorro C; Grupo de Analgesia y Sedación de la SEMICYUC. Monitorización del dolor. Recomendaciones del Grupo de Trabajo de Analgesia y Sedación de la SEMICYUC. Med Intensiva. 2006;30:379-85.
68. Carrasco G, Cabre L, Sobrepere G, Costa J, Molina R, Cruspinera A, et al. Synergistic sedation with propofol and midazolam in intensive care patients after coronary artery bypass grafting. Crit Care Med. 1998;26:844-51.
69. Tryba M, Kulka PJ. Critical care pharmacotherapy. A review. Drugs. 1993;45:338-52.
70. Hayashi Y, Maze M. Alpha 2 adrenoceptor agonists and anaesthesia. Br J Anaesth. 1993;71:108-18.
71. Tonner PH, Scholz J. Clinical perspectives of alpha-2 adrenoreceptor agonists. Curr Opin Anaesth. 1996;9:471-80.
72. Chamorro C, Romera MA, Martínez-Melgar JL. Sedación y analgesia de pacientes críticos en ventilación mecánica. ¿Tienen utilidad los alfa2 agonistas? Med Intensiva. 1999;23:59-61.
73. Martin J, Parsch A, Franck M, Wernecke KD, Fischer M, Spies C. Practice of sedation and analgesia in German intensive care units: results of a national survey. Crit Care. 2005;9:R117-23.
74. Chamorro C, Romera MA, Martínez-Melgar JL. Withdrawal syndrome and tolerance to sedatives and analgesics in Intensive Care Unit patients. Crit Care Med. 1999;27:2602-4.
75. Tryba M. Alpha2-adrenoceptor agonists in intensive care medicine: prevention and treatment of withdrawal. Baillieres Clin Anaesthesiol. 2000;14:459-70.
76. Stieger DS, Cantieni R, Frutiger A. Acute colonic pseudoobstruction (Ogilvie's syndrome) in two patients receiving high dose clonidine for delirium tremens. Intensive Care Med. 1997;23:780-2.
77. Siobal MS, Kallet RH, Kivett VA, Tang JF. Use of dexmedetomidine to facilitate extubation in surgical intensive-care-unit patients who failed previous weaning attempts following prolonged mechanical ventilation: a pilot study. Respir Care. 2006;51:492-6.
78. Romero C, Bugedo G, Bruhn A, Mellado P, Hernández G, Castillo L. Preliminary experience with dexmedetomidine treatment of confusional state and hyperadrenergic states at an intensive care unit. Rev Esp Anestesiol Reanim. 2002;49:403-6.
79. Chamorro C, Márquez J, Silva JA. Remifentanil is a useful alternative in critically ill patients when conventional sedative-analgesic regimens fail. Lifelines in Critical Care and Anaesthesia. 2002;4:8-9.